Has Inflammation a Significant Implication in Lung Cancer Evolution?

Status Active, not recruiting

Clinical Trial Summary

Systemic inflammation is a potential prognostic factor in cancer. Inflammation scores as the Glasgow score have been tested in cancer and specifically in lung cancer patients. The aim of the study is to look at the prognostic and predictive value of inflammation during cancer evolution, on the risk of complications leading to ICU admission and the risk of death.

Clinical Trial Description

Patients with newly diagnosed lung cancer will be eligible. All patients will have a blood sampling allowing testing inflammation and cytokine analyses at diagnosis, during work-up and in case of complication. ;

Study Design

Related Conditions & MeSH terms

Lung Neoplasms

Clinical Trial Details

NCT number	NCT02484872
Study type	Observational
Source	European Lung Cancer Working Party
Contact
Status	Active, not recruiting
Phase
Start date	May 2015
Completion date	December 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03357094` - Pulmonary Ventilation/Perfusion Imaging for the Prediction of Postoperative Residual Pulmonary Function	N/A
Recruiting	`NCT05543954` - 68Ga-FAPI-RGD PET/CT Imaging in the Lung Cancer Patients	Early Phase 1
Completed	`NCT01114958` - Pilot Study of Intra-Arterial Cisplatin With IV Thiosulfate in Patients With Lung Cancer or Lung Metastases	Phase 1
Recruiting	`NCT06004440` - Real World Registry for Use of the Ion Endoluminal System
Completed	`NCT02926768` - Phase I/II Study of CK-101 in NSCLC Patients and Other Advanced Solid Tumors	Phase 1
Not yet recruiting	`NCT02907606` - Urinary Circulating Tumor DNA Detection in Non-small Cell Lung Cancer: a Prospective Study	N/A
Active, not recruiting	`NCT02514512` - Lung Cancer Radiotherapy Using Realtime Dynamic Multileaf Collimator (MLC) Adaptation And Radiofrequency Tracking	N/A
Completed	`NCT02334007` - Extended Low-Molecular Weight Heparin VTE Prophylaxis in Thoracic Surgery	Phase 1/Phase 2
Completed	`NCT02531737` - Nintedanib (Vargatef®) Plus Docetaxel in Second Line of Treatment in Patients With Lung Cancer	Phase 2
Active, not recruiting	`NCT02284633` - Blood Sample Monitoring of Patients With EGFR Mutated Lung Cancer
Completed	`NCT02106143` - RejuvenAir™ System Lobectomy Safety and Histology Study	N/A
Completed	`NCT01933789` - Improving Communication About Serious Illness	N/A
Enrolling by invitation	`NCT01687647` - Sputum Cytometry Analysis in Lung Cancer Screening After Professional Asbestos Exposure	Phase 3
Completed	`NCT00351962` - Phase I/II Study of Fractionated Stereotactic Radiotherapy for Medically Inoperable NSCLC or Metastatic Lung Tumours	N/A
Completed	`NCT00385177` - Phase 1 Dose Escalation Study of SN2310 Injectable Emulsion in Patients With Advanced Solid Tumors	Phase 1
Terminated	`NCT00356525` - Chemotherapy Treatment in Re-occurring Non Small Cell Lung Cancer (NSCLC) After Previous Chemotherapy and Surgical Removal of the NSCLC Tumor	Phase 2
Completed	`NCT00243685` - Chemotherapy Drug Sensitivity Microculture (MiCK) Assay for Apoptosis	Phase 2/Phase 3
Completed	`NCT00129844` - Study of Motexafin Gadolinium (MGd) for Second Line Treatment of Non-Small-Cell Lung Cancer	Phase 2
Withdrawn	`NCT00090701` - A Phase 2, Open-Label, Multicenter Study of the GARFT Inhibitor in Patients With Metastatic Non-Small Cell Lung Cancer	Phase 2
Recruiting	`NCT01789229` - Establishment of a Tumor Bank for Tissue Samples